Home
Live Updates
FDA Accepts Isatuximab for Priority Review for Treatment of Transplant-Ineligible Multiple Myeloma : comparemela.com
FDA Accepts Isatuximab for Priority Review for Treatment of Transplant-Ineligible Multiple Myeloma
Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.
Related Keywords
United States ,
Dietmar Berger ,
Amgen Inc ,
Zydus Pharmaceuticals Inc ,
Janssen Pharmaceutical Companies ,
comparemela.com © 2020. All Rights Reserved.